Literature DB >> 18454341

Proarrhythmic potential of antimicrobial agents.

J Simkó1, A Csilek, J Karászi, I Lorincz.   

Abstract

Several antiarrhythmic and non-cardiovascular drug therapies including antimicrobial agents have been implicated as the causes for QT interval prolongation, torsades de pointes (TdP) ventricular tachycardia and sudden cardiac death. Most of the drugs that have been associated with the lengthening of the QT interval or development of TdP can also block the rapidly activating component of the delayed rectifier potassium current (IKr) in the ventricular cardiomyocytes. This article presents a review of the current literature on the QT interval prolonging effect of antimicrobials based on the results of the in vitro, in vivo studies and case reports. Our observations were derived from currently available Medline database. As we found, the most frequently QT interval prolonging antimicrobials are erythromycin, clarithromycin, fluoroquinolones, halofantrine, and pentamidine. Almost every antimicrobial-associated QT interval prolongation occurs in patients with multiple risk factors of the following: drug interactions, female gender, advanced age, structural heart disease, genetic predisposition, and electrolyte abnormalities. In conclusion, physicians should avoid prescribing antimicrobials having QT prolonging potential for patients with multiple risk factors. Recognition and appropriate treatment of TdP are also indispensable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454341     DOI: 10.1007/s15010-007-7211-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 2.  Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.

Authors:  Arsen Uvelin; Jasmina Pejaković; Vesna Mijatović
Journal:  J Anesth       Date:  2017-02-22       Impact factor: 2.078

Review 3.  [Drug-induced long QT syndrome. Relevancy in intensive care medicine].

Authors:  R Laszlo; S Laszlo; K Kettering; J Schreieck; R Riessen
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-01-19       Impact factor: 0.840

4.  Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.

Authors:  Maria Romøren; Morten Lindbæk; Hedvig Nordeng
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

5.  Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.

Authors:  John D Zeuli; John W Wilson; Lynn L Estes
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

6.  QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.

Authors:  Florine A Berger; Nico Monadian; Natasja M S de Groot; Bart Santbergen; Heleen van der Sijs; Matthijs L Becker; Annoek E C Broers; Teun van Gelder; Patricia M L A van den Bemt
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

7.  Illuminating drug action by network integration of disease genes: a case study of myocardial infarction.

Authors:  Rui-Sheng Wang; Joseph Loscalzo
Journal:  Mol Biosyst       Date:  2016-04-26

Review 8.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation.

Authors:  Dirk Bandorski; Reinhard Hoeltgen; Nicole Becker; Winfried Padberg; Harilaos Bogossian; Christoph Wiedenroth; Matthias Arlt; Christian Hamm; Werner Seeger; Hossein Ardeschir Ghofrani; Matthias Hecker; Henning Gall; Konstantin Mayer
Journal:  Biomed Res Int       Date:  2017-11-06       Impact factor: 3.411

10.  Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone.

Authors:  Jay W Mason; Rakesh Chugh; Anasuya Patel; Ranjeet Gutte; Ashima Bhatia
Journal:  Clin Transl Sci       Date:  2018-11-27       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.